1 Market Overview
1.1 Product Overview and Scope of Benign Prostatic Hyperplasia Treatment
1.2 Classification of Benign Prostatic Hyperplasia Treatment by Type
1.2.1 Overview: Global Benign Prostatic Hyperplasia Treatment Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Benign Prostatic Hyperplasia Treatment Revenue Market Share by Type in 2020
1.2.3 Drug Class
1.2.4 Minimally Invasive Surgeries
1.2.5 Laser Therapy
1.2.6 Others
1.3 Global Benign Prostatic Hyperplasia Treatment Market by Application
1.3.1 Overview: Global Benign Prostatic Hyperplasia Treatment Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Hospitals
1.3.3 Ambulatory Surgical Centers
1.3.4 Specialty Clinics
1.3.5 Others
1.4 Global Benign Prostatic Hyperplasia Treatment Market Size & Forecast
1.5 Global Benign Prostatic Hyperplasia Treatment Market Size and Forecast by Region
1.5.1 Global Benign Prostatic Hyperplasia Treatment Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Benign Prostatic Hyperplasia Treatment Market Size by Region, (2016-2021)
1.5.3 North America Benign Prostatic Hyperplasia Treatment Market Size and Prospect (2016-2026)
1.5.4 Europe Benign Prostatic Hyperplasia Treatment Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Benign Prostatic Hyperplasia Treatment Market Size and Prospect (2016-2026)
1.5.6 South America Benign Prostatic Hyperplasia Treatment Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Benign Prostatic Hyperplasia Treatment Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Benign Prostatic Hyperplasia Treatment Market Drivers
1.6.2 Benign Prostatic Hyperplasia Treatment Market Restraints
1.6.3 Benign Prostatic Hyperplasia Treatment Trends Analysis
2 Company Profiles
2.1 Abbott
2.1.1 Abbott Details
2.1.2 Abbott Major Business
2.1.3 Abbott Benign Prostatic Hyperplasia Treatment Product and Solutions
2.1.4 Abbott Benign Prostatic Hyperplasia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Abbott Recent Developments and Future Plans
2.2 Allergan plc
2.2.1 Allergan plc Details
2.2.2 Allergan plc Major Business
2.2.3 Allergan plc Benign Prostatic Hyperplasia Treatment Product and Solutions
2.2.4 Allergan plc Benign Prostatic Hyperplasia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Allergan plc Recent Developments and Future Plans
2.3 Astellas Pharma
2.3.1 Astellas Pharma Details
2.3.2 Astellas Pharma Major Business
2.3.3 Astellas Pharma Benign Prostatic Hyperplasia Treatment Product and Solutions
2.3.4 Astellas Pharma Benign Prostatic Hyperplasia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Astellas Pharma Recent Developments and Future Plans
2.4 Asahi Kasei Corporation
2.4.1 Asahi Kasei Corporation Details
2.4.2 Asahi Kasei Corporation Major Business
2.4.3 Asahi Kasei Corporation Benign Prostatic Hyperplasia Treatment Product and Solutions
2.4.4 Asahi Kasei Corporation Benign Prostatic Hyperplasia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Asahi Kasei Corporation Recent Developments and Future Plans
2.5 Boehringer Ingelheim GmbH
2.5.1 Boehringer Ingelheim GmbH Details
2.5.2 Boehringer Ingelheim GmbH Major Business
2.5.3 Boehringer Ingelheim GmbH Benign Prostatic Hyperplasia Treatment Product and Solutions
2.5.4 Boehringer Ingelheim GmbH Benign Prostatic Hyperplasia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Boehringer Ingelheim GmbH Recent Developments and Future Plans
2.6 GlaxoSmithKline
2.6.1 GlaxoSmithKline Details
2.6.2 GlaxoSmithKline Major Business
2.6.3 GlaxoSmithKline Benign Prostatic Hyperplasia Treatment Product and Solutions
2.6.4 GlaxoSmithKline Benign Prostatic Hyperplasia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 GlaxoSmithKline Recent Developments and Future Plans
2.7 Pfizer
2.7.1 Pfizer Details
2.7.2 Pfizer Major Business
2.7.3 Pfizer Benign Prostatic Hyperplasia Treatment Product and Solutions
2.7.4 Pfizer Benign Prostatic Hyperplasia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Pfizer Recent Developments and Future Plans
2.8 Sanofi
2.8.1 Sanofi Details
2.8.2 Sanofi Major Business
2.8.3 Sanofi Benign Prostatic Hyperplasia Treatment Product and Solutions
2.8.4 Sanofi Benign Prostatic Hyperplasia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Sanofi Recent Developments and Future Plans
2.9 Teva Pharmaceutical Industries
2.9.1 Teva Pharmaceutical Industries Details
2.9.2 Teva Pharmaceutical Industries Major Business
2.9.3 Teva Pharmaceutical Industries Benign Prostatic Hyperplasia Treatment Product and Solutions
2.9.4 Teva Pharmaceutical Industries Benign Prostatic Hyperplasia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 Teva Pharmaceutical Industries Recent Developments and Future Plans
2.10 Merck
2.10.1 Merck Details
2.10.2 Merck Major Business
2.10.3 Merck Benign Prostatic Hyperplasia Treatment Product and Solutions
2.10.4 Merck Benign Prostatic Hyperplasia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.10.5 Merck Recent Developments and Future Plans
2.11 Boston Scientific Corporation
2.11.1 Boston Scientific Corporation Details
2.11.2 Boston Scientific Corporation Major Business
2.11.3 Boston Scientific Corporation Benign Prostatic Hyperplasia Treatment Product and Solutions
2.11.4 Boston Scientific Corporation Benign Prostatic Hyperplasia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.11.5 Boston Scientific Corporation Recent Developments and Future Plans
2.12 Teleflex Incorporated
2.12.1 Teleflex Incorporated Details
2.12.2 Teleflex Incorporated Major Business
2.12.3 Teleflex Incorporated Benign Prostatic Hyperplasia Treatment Product and Solutions
2.12.4 Teleflex Incorporated Benign Prostatic Hyperplasia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.12.5 Teleflex Incorporated Recent Developments and Future Plans
2.13 Endo International
2.13.1 Endo International Details
2.13.2 Endo International Major Business
2.13.3 Endo International Benign Prostatic Hyperplasia Treatment Product and Solutions
2.13.4 Endo International Benign Prostatic Hyperplasia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.13.5 Endo International Recent Developments and Future Plans
2.14 Urologix
2.14.1 Urologix Details
2.14.2 Urologix Major Business
2.14.3 Urologix Benign Prostatic Hyperplasia Treatment Product and Solutions
2.14.4 Urologix Benign Prostatic Hyperplasia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.14.5 Urologix Recent Developments and Future Plans
2.15 LISA Laser
2.15.1 LISA Laser Details
2.15.2 LISA Laser Major Business
2.15.3 LISA Laser Benign Prostatic Hyperplasia Treatment Product and Solutions
2.15.4 LISA Laser Benign Prostatic Hyperplasia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.15.5 LISA Laser Recent Developments and Future Plans
2.16 Olympus
2.16.1 Olympus Details
2.16.2 Olympus Major Business
2.16.3 Olympus Benign Prostatic Hyperplasia Treatment Product and Solutions
2.16.4 Olympus Benign Prostatic Hyperplasia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.16.5 Olympus Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Benign Prostatic Hyperplasia Treatment Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 Benign Prostatic Hyperplasia Treatment Players Market Share
3.2.2 Top 10 Benign Prostatic Hyperplasia Treatment Players Market Share
3.2.3 Market Competition Trend
3.3 Benign Prostatic Hyperplasia Treatment Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Benign Prostatic Hyperplasia Treatment Revenue and Market Share by Type (2016-2021)
4.2 Global Benign Prostatic Hyperplasia Treatment Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Benign Prostatic Hyperplasia Treatment Revenue Market Share by Application (2016-2021)
5.2 Benign Prostatic Hyperplasia Treatment Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Benign Prostatic Hyperplasia Treatment Revenue by Type (2016-2026)
6.2 North America Benign Prostatic Hyperplasia Treatment Revenue by Application (2016-2026)
6.3 North America Benign Prostatic Hyperplasia Treatment Market Size by Country
6.3.1 North America Benign Prostatic Hyperplasia Treatment Revenue by Country (2016-2026)
6.3.2 United States Benign Prostatic Hyperplasia Treatment Market Size and Forecast (2016-2026)
6.3.3 Canada Benign Prostatic Hyperplasia Treatment Market Size and Forecast (2016-2026)
6.3.4 Mexico Benign Prostatic Hyperplasia Treatment Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Benign Prostatic Hyperplasia Treatment Revenue by Type (2016-2026)
7.2 Europe Benign Prostatic Hyperplasia Treatment Revenue by Application (2016-2026)
7.3 Europe Benign Prostatic Hyperplasia Treatment Market Size by Country
7.3.1 Europe Benign Prostatic Hyperplasia Treatment Revenue by Country (2016-2026)
7.3.2 Germany Benign Prostatic Hyperplasia Treatment Market Size and Forecast (2016-2026)
7.3.3 France Benign Prostatic Hyperplasia Treatment Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Benign Prostatic Hyperplasia Treatment Market Size and Forecast (2016-2026)
7.3.5 Russia Benign Prostatic Hyperplasia Treatment Market Size and Forecast (2016-2026)
7.3.6 Italy Benign Prostatic Hyperplasia Treatment Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Benign Prostatic Hyperplasia Treatment Revenue by Type (2016-2026)
8.2 Asia-Pacific Benign Prostatic Hyperplasia Treatment Revenue by Application (2016-2026)
8.3 Asia-Pacific Benign Prostatic Hyperplasia Treatment Market Size by Region
8.3.1 Asia-Pacific Benign Prostatic Hyperplasia Treatment Revenue by Region (2016-2026)
8.3.2 China Benign Prostatic Hyperplasia Treatment Market Size and Forecast (2016-2026)
8.3.3 Japan Benign Prostatic Hyperplasia Treatment Market Size and Forecast (2016-2026)
8.3.4 South Korea Benign Prostatic Hyperplasia Treatment Market Size and Forecast (2016-2026)
8.3.5 India Benign Prostatic Hyperplasia Treatment Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Benign Prostatic Hyperplasia Treatment Market Size and Forecast (2016-2026)
8.3.7 Australia Benign Prostatic Hyperplasia Treatment Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Benign Prostatic Hyperplasia Treatment Revenue by Type (2016-2026)
9.2 South America Benign Prostatic Hyperplasia Treatment Revenue by Application (2016-2026)
9.3 South America Benign Prostatic Hyperplasia Treatment Market Size by Country
9.3.1 South America Benign Prostatic Hyperplasia Treatment Revenue by Country (2016-2026)
9.3.2 Brazil Benign Prostatic Hyperplasia Treatment Market Size and Forecast (2016-2026)
9.3.3 Argentina Benign Prostatic Hyperplasia Treatment Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Benign Prostatic Hyperplasia Treatment Revenue by Type (2016-2026)
10.2 Middle East & Africa Benign Prostatic Hyperplasia Treatment Revenue by Application (2016-2026)
10.3 Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size by Country
10.3.1 Middle East & Africa Benign Prostatic Hyperplasia Treatment Revenue by Country (2016-2026)
10.3.2 Turkey Benign Prostatic Hyperplasia Treatment Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Benign Prostatic Hyperplasia Treatment Market Size and Forecast (2016-2026)
10.3.4 UAE Benign Prostatic Hyperplasia Treatment Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
【掲載企業】
Abbott、Allergan plc、Astellas Pharma、Asahi Kasei Corporation、Boehringer Ingelheim GmbH、GlaxoSmithKline、Pfizer、Sanofi、Teva Pharmaceutical Industries、Merck、Boston Scientific Corporation、Teleflex Incorporated、Endo International、Urologix、LISA Laser、Olympus
【免責事項】
https://www.globalresearch.jp/disclaimer